Gland Pharma reported a 47% year-on-year rise in Q1 FY27 net profit to ₹317 crore, with revenue up 20% to ₹1,800 crore. Growth was driven by its CDMO and B2B businesses, alongside strong US and Europe performance. EBITDA rose 33% to ₹489 crore.
Gland Pharma Q1 net profit jumps 47% on strong CDMO, B2B growth
Source: Mint